Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
163 results about "Activin a" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Anti-activin a antibodies and uses thereof
ActiveUS20090234106A1Loss of body weightMassive lossAntipyreticAnalgesicsNucleotideAntibody fragments
The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.
Owner:AMGEN INC
Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A
The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and / or Activin A activity.
Owner:REGENERON PHARM INC
Anti-activin A antibodies and uses thereof
ActiveUS8309082B2No improvement in cachexiaReduce weightAntipyreticAnalgesicsAntibody fragmentsPolynucleotide
The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.
Owner:AMGEN INC
Methods for increasing thermogenic adipocytes
ActiveUS8178488B2High expressionIncreasing thermogenic adipocytesOrganic active ingredientsPeptide/protein ingredientsNODALDisease
In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
Owner:ACCELERON PHARMA INC
Methods for dosing an activin-actriia antagonist and monitoring of treated patients
InactiveUS20100015144A1Undesired effectImprove the level ofPeptide/protein ingredientsAntibody mimetics/scaffoldsHematologyAntagonist
In certain aspects, the present invention provides methods for dosing a patient with an activin-ActRIIa antagonist and methods for managing patients treated with an activin-ActRIIa anatagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.
Owner:ACCELERON PHARMA INC
Novel activin receptor and uses thereof
The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.
Owner:AMGEN INC
Variant activin receptor polypeptides
Owner:AMGEN INC
Methods for treating fatty liver disease
InactiveUS20110129469A1Significant positive effectOrganic active ingredientsPeptide/protein ingredientsMyostatinFatty liver
In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.
Owner:ACCELERON PHARMA INC
Stem cell-derived retin retinal pigment epithelial cells
ActiveUS20110027333A1Improve retinal functionBiocideSenses disorderDirected differentiationRetinal pigment epithelial cell
The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGFβ superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGFβ superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
ActiveUS20140348827A1Size of tumor massOrganic active ingredientsPeptide/protein ingredientsMyostatinDisease
The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Owner:AMGEN INC
Medicament and method for treating renal disease
A medicament for treating a renal disease, comprising a therapeutically effective amount of an activin inhibitor as an active ingredient. Also, a method for treating a renal disease, comprising administering a therapeutically effective amount of an activin inhibitor to a patient suffering from renal disease is disclosed. The activin inhibitor may be follistatin, an anti-activin antibody, an inhibitor to activin receptor or an anti-activin receptor antibody, an inhibitor to signal transduction relating to activin receptor, an activin production inhibitor in kidney, and the like.
Owner:AJINOMOTO CO INC
Variant activin receptor polypeptides and uses thereof
Owner:AMGEN INC
Method for detection of melanoma
The present invention provides non-invasive methods for detecting, monitoring, staging, and diagnosing malignant melanoma in a skin sample of a subject. The methods include analyzing expression in skin sample of one or more melanoma skin markers. The melanoma skin markers include IL-1 RI, endothelin-2, ephrin-A5, IGF Binding Protein 7, HLA-A0202 heavy chain, Activin A (βA subunit), TNF RII, SPC4, and CNTF Rα. The skin sample can include nucleic acids, and can be a human skin sample from a lesion suspected of being melanoma.
Owner:DERMTECH INT
Renal progenitor cells from embryonic stem cells
The present invention relates to compositions and methods for inducing the differentiation of stem cells into renal progenitor cells. In particular, the present invention provides compositions containing activin-a, retinoic acid, and bmp-7, and variants thereof, for differentiating stem cells into renal cells containing tubular epithelia. In certain embodiments, the present invention provides stem cells cultured with compositions used to treat renal disease.
Owner:RGT UNIV OF MICHIGAN
Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
InactiveUS20180008672A1Good effectIncrease volumePeptide/protein ingredientsAntibody mimetics/scaffoldsAntigen Binding FragmentAntigen binding
Owner:REGENERON PHARM INC
Mutated acvr1 for diagnosis and treatment of fibrodyplasia ossificans progressiva (FOP)
This invention is directed to mutated Activin A type I receptor proteins (ACVR1) and isolated nucleic acids encoding same. The invention also relates to the use of mutated ACVR1 in the diagnosis and treatment of Fibrodysplasia Ossificans Progressiva (FOP).
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Variant activin receptor polypeptides and uses thereof
ActiveUS20090227497A1Avoid wastingOrganic active ingredientsPeptide/protein ingredientsMyostatinADAMTS Proteins
The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Owner:AMGEN INC
Retinal pigment epithelial cells differentiated from embryonic stem cells with nicotinamide and activin A
ActiveUS8956866B2Improve retinal functionSenses disorderPharmaceutical delivery mechanismDirected differentiationRetinal pigment epithelial cell
The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGFβ superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGFβ superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT
Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases
ActiveUS20110262393A1Neurocytoxicity caused by amyloid-beta is preventedPhosphorylation of tau protein in neurons is preventedBiocideNervous disorderDiseaseCulture fluid
Provided are a pharmaceutical composition for prevention and treatment of a neural disease including at least one selected from the group consisting of mesenchymal stem cells (MSCs), a culture solution of the MSCs, activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin-1, WISP1, progranulin, IL-4, a factor inducing expression thereof, and any combination thereof, and a method therefor.
Owner:MEDIPOST
Variant activin receptor polypeptides and uses thereof
The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Owner:AMGEN INC
Induction culture medium and method for inducing human fat mesenchymal stem cells to generate insulin secreting cells
ActiveCN104263697AArtificial cell constructsSkeletal/connective tissue cellsPentagastrin stimulation testInsulin Secreting Cell
The invention discloses an induction culture medium which comprises a solvent DMEM (dulbecco's modified eagle medium)-high sugar culture medium, platelets, all-trans vitamin A acid, activin A, glicetin I, a fibroblast growth factor, beta cytosine, an insuline-like growth factor, nicotinamide, polypeptide, pentagastrin and mercaptoethanol. Physical oscillation and collagenase / pancreatin dual digestion are performed to efficiently separate fat mesenchymal stem cells from human fat tissues. The fat mesenchymal stem cells are cultured for proliferation and subcultivation, and the induction culture medium is utilized to induce the fat mesenchymal stem cells to become insulin secreting cells, so that more than 40% of the fat stem cells are induced to differentiate into the insulin secreting cells.
Owner:胡振波
Novel Hybrid ActRIIB Ligand Trap Proteins For Treating Muscle Wasting Diseases
The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin / activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.
Owner:ALIVEGEN INC
Human cancer stem cell culture compositions comprising Erbb2 variants and methods of use thereof
The present invention provides compositions and methods for the culture and maintenance of cancer stem cells. More particularly, the present invention provides the identification of cancer stem cell specific markers and methods of recognizing the same for the detection of tumors, for facilitating the prognosis of a patient with a tumor, and for the treatment of various cancers. The invention also provides antibodies that specifically recognize the disulfide linked Erbb2Δ16 homodimer, an Erbb2Δ16 / Erbb3 heterodimer, or post-translational modifications of Erbb2 that are specific to Erbb2 of variant hESCs. In addition, the invention provides a modified defined media useful in the absence of a feeder layer and in the absence of serum or serum replacement, that comprises a basal salt nutrient solution, bFGF, IGF-I, and Activin A, and wherein the composition does not comprise heregulin. The invention further relates to the use of an Erbb2 variant isoform to generate robust cell cultures that are independent of heregulin.
Owner:VIACYTE INC
Variant activin receptor polypeptides
ActiveUS20110183897A1Avoid wastingOrganic active ingredientsPeptide/protein ingredientsDiseaseMyostatin
The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Owner:AMGEN INC
Novel activin receptor and uses thereof
ActiveUS20110281796A1Add additional massHigh strengthOrganic active ingredientsPeptide/protein ingredientsMyostatinDisease
Owner:AMGEN INC
Sirna-based therapy of fibrodyplasia ossificans progressiva (FOP)
This invention is directed to mutated Activin A type I receptor proteins (ACVR1) and isolated nucleic acids encoding same. The invention also relates to compositions and methods for siRNA-based regulation of mutated ACVR1 expression in the treatment of Fibrodysplasia Ossificans Progressiva (FOP).
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Culture medium for inducing human umbilical cord mesenchymal stem cells to differentiate into islet-like cells and induction method therefor
PendingCN105670986AImprove induction efficiencyEasy to getVertebrate cellsArtificial cell constructsBeta-Nerve Growth FactorUmbilical cord
The invention discloses a medium for inducing human umbilical cord mesenchymal stem cells to differentiate into islet-like cells and an inducing method thereof. The medium contains activin A, epidermal growth factor, β-nerve growth factor, nicotinamide, 1% insulin-transferrin-selenium, and 10 μg / L basic fibroblast growth factor UltraCULTURE medium. The induction method is as follows: the mesenchymal stem cells are induced, differentiated and cultured using the above-mentioned induction medium. The induction medium of the invention contains simple induction factors, does not contain toxic and harmful substances, and is safer. The method of the present invention for inducing human umbilical cord mesenchymal stem cells to differentiate into islet-like cells can obtain aggregated islet-like cells in 21 days, and partially mature and differentiated islet-like cells can be obtained in 28 days. A standardized and novel induction method has been established. Broad clinical application prospects.
Owner:王意忠
Methods of diagnosing and treating complications of pregnancy
The present invention discloses methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin, endothelial nitric oxide synthase, PGI2, TGF-betal, TGF-beta3, activin A, BMP2, BMP7, and sFlt-1 expression levels or biological activity. Also disclosed are methods of diagnosing a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, that include the measurement of any one or more of the following: soluble endoglin, endothelial nitric oxide synthase, PGI2, TGF-betal, TGF-beta3, activin A, BMP2, BMP7, and sFlt-1 expression levels or biological activity.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC +1
Method for inducing alveolar epithelial progenitor cells
This invention provides a method for stably producing alveolar epithelial progenitor cells from pluripotent stem cells, including steps of culturing pluripotent stem cells in (1) a medium containing activin A and a GSK3β inhibitor, (2) a medium containing a BMP inhibitor and a TGFβ inhibitor, and (3) a medium containing BMP4, retinoic acid, and a GSK3β inhibitor.
Owner:KYOTO UNIV
Method for transforming umbilical cord mesenchymal stem cells into islet cells
InactiveCN104988110AA large amountQuality improvementArtificial cell constructsVertebrate cellsNiacinamideIslet cells
The invention relates to a method for transforming umbilical cord mesenchymal stem cells into islet cells. The method comprises the steps that after the umbilical cord mesenchymal stem cells are separated under the aseptic condition and subcultured, the induction is conducted, wherein 1 beta-nerve growth factors, activin A, niacinamide and epidermal growth factors are added into a DMEM / F12 culture medium containing fetal calf serum for conducting the induction culture; 2 a DMEM / F12 culture medium containing niacinamide, alkaline fibroblast growth factors and insulin-transferrin-selenium is added in for continuous culture till the cell transformation is ended, and islet cell sap is obtained. By means of the method, the number of the obtained islet cells is large, the quality of the islet cells is good, more insulin can be secreted, and the method is of great importance in clinic transformation of the umbilical cord mesenchymal stem cells for treating the 1 type diabetes.
Owner:SHEN ZHEN ISTEM REGENERATIVE MEDICINE SCI TECH CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com